NL-OMON28736已完成不适用
The use of hydrochlorothiazide and skin cancer risk among patients with type 2 diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 71,648
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Type 2 diabetes patients treated in the primary care
排除标准
- •Type 2 diabtes patientes who had a history of skin cancer before cohort entry
研究者
相似试验
已完成
不适用
Hydrochlorothiazide and Risk of Skin CancerHypertensionMelanomaNon-melanoma Skin CancerNCT04334824Canadian Network for Observational Drug Effect Studies, CNODES2,953,748
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-CZDAIICHI SANKYO EUROPE GmbH2,220
进行中（未招募）
1 期
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEficacia y seguridad de Hidroclorotiazida, utilizada como terapia adicional, en pacientes con hipertensión moderada a severa no controlados adecuadamente con Olmesartan MEdoxomil 40 mg en monoterapiaEssential hypertensionHipertensión esencialMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-ESDAIICHI SANKYO EUROPE GmbH1,500
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-DEDAIICHI SANKYO EUROPE GmbH1,500
进行中（未招募）
1 期
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEUCTR2006-003876-37-FRDAIICHI SANKYO EUROPE GmbH1,500